TERT-Promoter Mutational Status in Glioblastoma - Is There an Association With Amino Acid Uptake on Dynamic 18F-FET PET?

OBJECTIVE: The mutation of the 'telomerase reverse transcriptase gene promoter' (TERTp) has been identified as an important factor for individual prognostication and tumorigenesis and will be implemented in upcoming glioma classifications. Uptake characteristics on dynamic 18F-FET PET have been shown to serve as additional imaging biomarker for prognosis. However, data on the correlation of TERTp-mutational status and amino acid uptake on dynamic 18F-FET PET are missing. Therefore, we aimed to analyze whether static and dynamic 18F-FET PET parameters are associated with the TERTp-mutational status in de-novo IDH-wildtype glioblastoma and whether a TERTp-mutation can be predicted by dynamic 18F-FET PET.
METHODS: Patients with de-novo IDH-wildtype glioblastoma, WHO grade IV, available TERTp-mutational status and dynamic 18F-FET PET scan prior to any therapy were included. Here, established clinical parameters maximal and mean tumor-to-background-ratios (TBRmax/TBRmean), the biological-tumor-volume (BTV) and minimal-time-to-peak (TTPmin) on dynamic PET were analyzed and correlated with the TERTp-mutational status.
RESULTS: One hundred IDH-wildtype glioblastoma patients were evaluated; 85/100 of the analyzed tumors showed a TERTp-mutation (C228T or C250T), 15/100 were classified as TERTp-wildtype. None of the static PET parameters was associated with the TERTp-mutational status (median TBRmax 3.41 vs. 3.32 (p=0.362), TBRmean 2.09 vs. 2.02 (p=0.349) and BTV 26.1 vs. 22.4 ml (p=0.377)). Also, the dynamic PET parameter TTPmin did not differ in both groups (12.5 vs. 12.5 min, p=0.411). Within the TERTp-mutant subgroups (i.e., C228T (n=23) & C250T (n=62)), the median TBRmax (3.33 vs. 3.69, p=0.095), TBRmean (2.08 vs. 2.09, p=0.352), BTV (25.4 vs. 30.0 ml, p=0.130) and TTPmin (12.5 vs. 12.5 min, p=0.190) were comparable, too.
CONCLUSION: Uptake characteristics on dynamic 18F-FET PET are not associated with the TERTp-mutational status in glioblastoma However, as both, dynamic 18F-FET PET parameters as well as the TERTp-mutation status are well-known prognostic biomarkers, future studies should investigate the complementary and independent prognostic value of both factors in order to further stratify patients into risk groups.

Introduction

According to the updated 2016 WHO classification of brain tumors, the molecular genetic profile plays a major role for the glioma characterization and highly affects the further clinical management and treatment strategies (1, 2). Beyond the current molecular genetic stratification using the isocitrate dehydrogenase (IDH)-mutational status and 1p/19q-codeletion, additional molecular genetic markers are increasingly identified and gradually gain access into clinical routine. In particular, mutations of the telomerase reverse transcriptase gene promoter (TERTp) were identified as important factor within the tumorigenesis and individual prognostication (3, 4), with inferior outcome in combination with an IDH-wildtype status (5, 6), which will be implemented in upcoming glioma classifications.

As recommended by the Response assessment in Neurooncology (RANO) working group in their clinical guidelines (7–9), molecular imaging using positron-emission-tomography (PET) with radiolabeled amino acids such as O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) is increasingly used for the comprehensive evaluation and characterization of brain neoplasms beyond morphological standard imaging with MRI, e. g. for treatment planning (10–13), but also for noninvasive tumor characterization at initial diagnosis (14–20). Recent studies indicated that the IDH-mutational status is highly associated with 18F-FET PET uptake in brain tumors, especially with the ‘minimal time to peak’ (TTPmin) on dynamic 18F-FET PET, and has thus a high diagnostic power for the identification of IDH-wildtype gliomas (21). With regard to TERTp, no study has hitherto evaluated the association of amino acid uptake on PET and the TERTp-mutational status. Hence, we aimed to assess whether the uptake characteristics on static and dynamic 18F-FET PET are likewise associated with the TERTp-mutation status in a homogeneous group of de-novo, IDH-wildtype glioblastoma and whether PET can predict the TERTp-mutation status.

Methods and Materials

Patients

Patients with histologically confirmed, newly diagnosed IDH-wildtype glioblastoma WHO grade IV with available molecular genetic analyses of the TERT-promoter mutation status as well as a dynamic 18F-FET PET scan prior to stereotactic biopsy or surgical resection were identified. All patients have given written informed consent prior to the PET examination as part of the clinical routine. Ethical approval of the retrospective study protocol was given by the institutional review board of the LMU.

Histological Confirmation, Tumor Grading and Molecular Genetic Analysis

Stereotactic biopsy procedures and microsurgical resections were performed at the Department of Neurosurgery, LMU Munich, Germany. As part of the clinical routine, histopathological and molecular genetic evaluations were performed at the Institute of Neuropathology, LMU Munich, Germany, and were initially classified according to the 2007 WHO classification of brain tumors (22) and were re-classified according to the updated 2016 WHO classification (1). The IDH-mutation status and TERT-promoter methylation were analyzed in clinical routine according to standard protocols (23–25). For further specification regarding the histopathological workup see also (26, 27).

18F-FET PET Image Acquisitionand Data Analysis

18F-FET PET scans were performed at the Department of Nuclear Medicine, LMU. Data of the dynamic 18F-FET PET scans were acquired using an ECAT Exact HR+ scanner (Siemens). After a 15-min transmission scan with a 68Ge rotating rod source, approximately 180 MBq of 18F-FET were injected. Dynamic emission recording was accomplished after tracer injection up to 40 min post injection in 3-D mode consisting of 16 frames (7 x 10 s; 3 x 30 s; 1 x 2 min; 3 x 5 min; 2 x 10 min). Two-dimensional filtered back-projection, reconstruction algorithms using a 5 mm Hann Filter were used for image reconstruction and corrected for photon attenuation and model-based scatter. The mean background activity (BG) was assessed using 6 large crescent-shaped regions of interests (ROI) in the frontal lobe of the healthy contralateral hemisphere fused to a volume of interest (VOI), in which the mean BG was derived (28). The biological tumor volume (BTV) was estimated by a semiautomatic threshold-based delineation of a volume of interest (VOI) using a standardized uptake value (SUV) threshold of 1.6 x BG, as previously described as optimal threshold (29). The maximal SUV (SUVmax) and mean SUV (SUVmean) as derived within the BTV were then divided by the BG resulting in mean and maximal tumor-to-background ratio (TBRmean/TBRmax). Data on dynamic PET was evaluated using the software PET Display Dynamic implemented in the Hermes workstation: in early summation images (10-30 min p.i.), a 90% isocontour region of interest was created to extract the time-activity-curves (TACs) on a slice-by-slice manner. Then, the time to peak (TTP) was assessed on each slice of the tumor and the shortest TTP in at least 2 consecutive slices was defined as minimal TTP (TTPmin), see also (30, 31).

Statistics

SPSS for Windows (version 23.0; SPSS, Chicago, IL) was used for statistical analyses. Descriptive statistics are displayed as median (range). Normal distribution was assessed using the Shapiro-Wilk-test. The unpaired Wilcoxon-test was used for independent and not-normally distributed continuous parameters. Receiver operating curves (ROC) analyses were used to assess the diagnostic power of continuous parameters, the ‘Area under the curve’ (AUC) served as quantitative measure for the diagnostic power. Statistical significance was defined as a two-tailed p-value <0.05.

Results

One-hundred patients with de-novo, IDH-wildtype glioblastoma, WHO grade IV were included (62/100 (62.0%) male, 38/100 (38.0%) female). The median age was 62.0 (range, 30.1-82.7) years. Tissue samples for histological and molecular genetic analyses were obtained by stereotactic biopsy in 74/100 (74.0%) and by surgical resection in 26/100 (26.0%) cases. Overall, 15/100 (15%) did not comprise a TERTp-mutation and were classified as TERTp-wildtype. Of the remaining 85/100 (85%) patients with TERTp-mutation, 62/85 (72.9%) showed a C228T-mutation and 23/85 (27.1%) showed a C250T-mutation.

Overall 18F-FET-Uptake Characteristics

All included gliomas were 18F-FET-positive providing a median TBRmax of 3.37 (2.06-7.07), a median TBRmean of 2.06 (range, 1.70-2.92) and a median BTV of 25.8 (range, 3.8-133.3) ml. In the dynamic analysis, median TTPmin was 12.5 (range, 3.0-35.0) minutes with a small proportion of late TTPmin ≥ 25 minutes in 13/100 (13.0%) cases only.

18F-FET-Uptake Characteristics Comparing TERTp-Mutant and TERTp-Wildtype Glioblastomas and Predictability of TERTp Mutational Status

Comparing glioblastomas with TERTp-mutation (n=85) and those without (n=15) revealed no statistically significant difference in terms of median TBRmax (3.41 (range, 2.06-7.07) vs. 3.32 (range, 2.32-4.67), p=0.362), TBRmean (2.09 (range, 1.70-2.92) vs. 2.02 (range, 1.79-2.56), p=0.349) and BTV (26.1 (range, 3.8-133.3) ml vs. 22.4 (range, 3.9-75.7) ml, p=0.377). Not only the evaluated static PET parameters, but also the dynamic parameter TTPmin did not differ between those two groups (12.5 (range, 3.0-35.0) min vs. 12.5 (range, 7.5-25.0) min, p=0.411). By consequence, the ROC-analysis to assess the diagnostic power of 18F-FET PET for the prediction of the TERTp mutational status did not reveal reliable thresholds for the differentiation between TERTp-mutant and TERTp-wildtype glioblastomas. Analyzing the static parameters TBRmax, TBRmean and BTV, the AUC ranged between 0.572 and 0.576 only. Also, for the dynamic parameter TTPmin the AUC reached only 0.562 at a best cut-off at 7.5 min. Further specifications can be found in and . Patient examples can be found on .

Table 1

Influence of TERT-mutation on 18F-FET-uptake characteristics [median (range)].

	Overall (n=100)	TERT-mutation (n=85)	TERT-wildtype (n=15)	Level of significance
TBRmax	3.37 (2.06-7.07)	3.41 (2.06-7.07)	3.32 (2.32-4.67)	p=0.362
TBRmean	2.06 (1.70-2.92)	2.09 (1.70-2.92)	2.02 (1.79-2.56)	p=0.349
BTV	25.8 (3.8-133.3) ml	26.1 (3.8-133.3) ml	22.4 (3.9-75.7) ml	p=0.377
TTPmin	12.5 (3.0-35.0) min	12.5 (3.0-35.0) min	12.5 (7.5-25.0) min	p=0.411

Table 2

Diagnostic power of 18F-FET PET for detection TERTp mutation.

Parameter	Best cut-off value	Area under the curve	Level of significance
TBRmax	3.60	0.574	p=0.323
TBRmean	2.21	0.576	p=0.297
BTV	24.1 ml	0.572	p=0.359
TTPmin	7.5 min	0.562	p=0.391

Figure 1

(A) a patient with TERTp-mutant glioblastoma (TBRmax 4,1; TBRmean 2,3; BTV 15,4 ml, TTPmin 5 min) shows comparable, only slightly diverging imaging features as (B), a patient with TERTp-wildtype glioblastoma (TBRmax 2,9; TBRmean 1,9; BTV 12,3 ml, TTPmin 10 min).

18F-FET-Uptake Characteristics Comparing TERT-Mutation Subtypes (C228T vs. C250T)

Comparing the two subtypes of TERT-promoter mutation C228T (n=62) & C250T (n=23), there was also no statistically significant difference in terms of median TBRmax (3.33 (range, 2.06-5.51) vs. 3.69 (range, 2.37-7.07), p=0.095), TBRmean (2.08 (range, 1.70-2.56) vs. 2.09 (range, 1.79-2.92), p=0.352) or BTV (25.4 (range, 3.8-133.3) ml vs. 30.0 (range, 5.7-102.1) ml, p=0.130). On dynamic PET analyses, the median TTPmin was also statistically comparable between those two mutation subtypes (12.5 (range, 7.5-35.0) min vs. 12.5 (range, 3.0-35.0) min, p=0.190). For further specifications, please see .

Table 3

Influence of TERT-mutation subtypes on 18F-FET-uptake characteristics [median (range)].

	TERT-mutation overall (n = 85)	C228T (n = 62)	C250T (n = 23)	Level of significance
TBRmax	3.41 (2.06-7.07)	3.33 (2.06-5.51)	3.69 (2.37-7.07)	p=0.095
TBRmean	2.09 (1.70-2.92)	2.08 (1.70-2.56)	2.09 (1.79-2.92)	p=0.352
BTV	26.1 (3.8-133.3) ml	25.4 (3.8-133.3) ml	30.0 (5.7-102.1) ml	p=0.130
TTPmin	12.5 (3.0-35.0) min	12.5 (7.5-35.0) min	12.5 (3.0-35.0) min	p=0.190

Discussion

This is the first study evaluating the association of amino acid uptake by means of 18F-FET PET and the TERTp-mutational status in glioma patients. As the TERTp-mutational status has shown additional prognostic value in IDH-wildtype gliomas/glioblastomas (5, 6, 32, 33), a non-invasive tool for the prediction of a TERTp-mutation would be helpful for the clinical management of glioma patients. In our large cohort with homogeneous histological and molecular genetic profile (i.e. WHO grade IV glioblastoma, IDH-wildtype only), we observed a high proportion of patients with TERTp mutation of 85%, which is in line with the proportion of patients with TERTp mutation in the current literature (4). Moreover, within the group of TERTp mutant glioblastomas, the C228T-mutation was present more frequently (72.9%) than the C250T-mutation (27.1%), which is also in line with the distribution within IDH-wildtype glioblastomas as described in the current literature (6, 34).

Comparing the TERTp-mutational status with the static PET parameters in terms of uptake intensity (TBRmax and TBRmean) and tumor extent (BTV), we observed a high overlap between TERTp-mutant and TERTp-wildtype tumors so that no cutoff could be found to differentiate between those groups. Moreover, TTPmin on dynamic PET was also indifferent between TERTp-mutant and TERTp-wildtype glioblastomas. Taken together, both groups presented with comparable imaging findings and could not be distinguished on 18F-FET PET. This leads to the assumption that dynamic 18F-FET PET cannot predict the TERTp-mutational status in IDH-wildtype glioblastoma. Taking a closer look at the IDH-mutational status, however, recent studies indicated that the IDH-mutational status can be identified non-invasively by dynamic 18F-FET PET with a relatively high diagnostic accuracy. In particular, the prognostically poor IDH-wildtype status can be predicted by a short TTPmin on dynamic 18F-FET PET (21).

When analyzing the TERTp-mutation subtypes (i.e. C228T & C250T), expectedly, no difference in terms of uptake-intensity (TBRmax & TBRmean) and tumor extent (i.e. BTV) on PET could be observed; also, TTPmin on dynamic PET was indifferent between C228T & C250T mutations. This finding, however, is not surprising, as these two mutations of hot spot promoter regions (C228T and C250T) are basically responsible for the same molecular mechanism (32, 33).

In general, one could speculate that the pathophysiological changes that are accompanied with TERTp mutations and their influence on cell regulation might also affect the cellular metabolism in terms of amino acid metabolism. Moreover, one could argue that both static and dynamic 18F-FET PET parameters were described to be of prognostic value in the further disease course of glioma patients; as the same is true for TERTp mutations, a certain intercorrelation does not seem unlikely. On a molecular level, the TERT as a catalytic subunit of the telomerase enzyme complex is critically involved in telomere maintenance and lengthening. Abnormal upregulation and activity of TERT as a consequence of TERTp-mutations are considered one of the mechanisms of cellular immortality in cancer cells during division, particularly in gliomas (35–37). With regard to PET imaging, the activity and/or expression of the large neutral amino acid transporter (LAT) at the tumor cells and at the brain capillary endothelial cells (38) is considered a key factor responsible for the intracellular uptake of amino acids in gliomas (39). The very exact mechanisms and the histopathological or even molecular genetic correlate resulting in diverging uptake dynamics of 18F-FET are not fully clarified yet and may be influenced by further factors such as vascularization. Our study findings suggest that the presence or, vice versa, the absence of TERTp-mutation in glioblastoma and the accompanying features on a cellular basis, although prognostically relevant, do neither result in an altered level of amino acid metabolism nor in changes of uptake dynamics on 18F-FET PET.

Notably, there is an occurrence of TERTp-mutations in different tumor types as well, also in molecular subgroups with superior prognosis compared to IDH-wildtype gliomas, e. g. in IDH-mutant gliomas. Interestingly, among IDH-mutant gliomas, IDH-mutant gliomas with TERTp-mutation comprise a superior clinical outcome compared to IDH-mutant glioma without TERTp-mutation, also with emphasis on the particular histological features (5). Therefore, the presence of TERTp-mutations in brain tumors per se is not necessarily linked to a more aggressive course in general. Particularly, in the group of oligodendroglial tumors (i.e. gliomas with both IDH-mutation and 1p/19q-codeletion), basically every tumor presents with TERTp-mutation. This molecular genetic subgroup is associated with favorable outcome compared to e.g. IDH-wildtype gliomas (32, 40), despite a basically general presence of TERTp mutations. These phenomena also warrant further investigation of PET-based imaging characteristics in the subgroup of IDH-mutant gliomas. First preliminary data using radiomic features on MRI could show certain moderate diagnostic power for the detection of TERTp mutations particularly in low-grade/IDH-mutant gliomas (41, 42).

Moreover, a vast body of literature exists dealing with radiomics, deep learning and machine learning with special emphasis on (18F-FET) PET and hybrid imaging in neuro-oncology (43–49), not just for the differentiation of treatment-related changes from real progression (44, 50, 51), but also for the predication of prognostically relevant mutations such as the IDH-mutation (52). Hence, it needs to be evaluated, if further PET-based analyses with the extraction of radiomic features may add value to the conventional image analysis in order to non-invasively identify the TERTp-mutational status. Interestingly, the predictability of key mutations using standard and advanced PET quantification also seems to vary depending on the used radioligands (53–57).

Particularly, as dynamic 18F-FET PET was previously reported to show a high prognostic value in gliomas in addition to the clinically most important molecular genetic biomarkers according to the 2016 WHO classification [IDH-mutation and 1p/19q-codeletion status (14, 26)], it would be interesting to evaluate whether the additional prognostic value of PET remains even after further subgroup stratification according to the TERTp mutation status. In order to test this hypothesis, further studies with a larger number of patients (particularly in the relatively small TERTp-wildtype subgroup) are needed to perform multivariate analyses.

Limitations arise from the retrospective study design. Moreover, as mentioned above, the absolute number of tumors without TERTp mutations is relatively low (i.e. n=15 vs. n=85), however, this proportion is in line with the previously reported distribution of TERTp mutations in glioblastoma. In the current manuscript, only filtered-back projection (FBP) reconstructions were used due to the applied scanner; quantification of PET parameters could potentially be diverging using other reconstruction algorithms such as ordered subset expectation maximization (OSEM).

Conclusion

The prognostically relevant TERTp-mutational status in IDH-wildtype glioblastoma is not associated with uptake characteristics on dynamic 18F-FET PET. As both, dynamic 18F-FET PET parameters as well as the TERTp-mutation status are well-known prognostic biomarkers, but show no association in our analysis, it seems highly interesting to evaluate in larger studies if both factors are independent predictors of patients’ survival and can thereby further stratify patients into risk groups.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors upon reasonable request.

Ethics Statement

The studies involving human participants were reviewed and approved by Ethics committee, LMU Munich. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author Contributions

Conceptualization, MU and NA. Methodology, MU, VR, KR, BS, LM, LB, MB, VW, and WK. Formal analysis, MU, VR, KR, and NA. Resources, all authors. Writing—original draft preparation, MU and NA. Writing—review and editing, all authors. Visualization, MU and NA. Supervision, NA, MN, JH, JT, and PB. Project administration, MU and NA. All authors contributed to the article and approved the submitted version.

Conflict of Interest

NA is a member of the Neuroimaging Committee of the EANM.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.